Atrium TherapeuticsRNA +0.16%12 Altman Z-Score is 2.66 as of Jun. 25, 2026, which is 4% below its 10-year median of 2.76. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 935 Biotechnology companies, Atrium Therapeutics ranks better than 50.48% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Warning Sign:
Altman Z-score of 2.66 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.
Atrium Therapeutics has a Altman Z-Score of 2.66, indicating it is in Grey Zones. This implies that Atrium Therapeutics is in some kind of financial stress. If it is below 1.81, the company may face bankrupcy risk.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Atrium Therapeutics's Altman Z-Score or its related term are showing as below:
RNA'
s Altman Z-Score Range Over the Past 10 Years
Min: 2.66 Med: 2.76 Max: 2.76
Current: 2.66
During the past 3 years, Atrium Therapeutics's highest Altman Z-Score was 2.76. The lowest was 2.66. And the median was 2.76.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Atrium Therapeutics Altman Z-Score Related Terms
Atrium Therapeutics Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Atrium Therapeutics's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RNA vs RNAC, KROS, ARCT: Altman Z-Score Comparison
For the Biotechnology subindustry, Atrium Therapeutics's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atrium Therapeutics Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atrium Therapeutics's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Atrium Therapeutics's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Atrium Therapeutics's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.9018
+
1.4
*
0.0415
+
3.3
*
-0.2467
+
0.6
*
3.7584
+
1.0
*
0.0755
=
2.66
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Atrium Therapeutics (RNA) has a Altman Z-Score of 2.66 as of Jun. 25, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Atrium Therapeutics and its competitors. This is near median its historical median of 2.76. Over the past decade, Atrium Therapeutics' Altman Z-Score has ranged from 2.66 to 2.76. According to the industry distribution chart, Atrium Therapeutics ranks #463 out of 935 companies in the Biotechnology industry, placing it in the top 49.5%.
Is Atrium Therapeutics' Altman Z-Score too high?
Atrium Therapeutics' current Altman Z-Score of 2.66 is near median its 10-year median of 2.76. Over the past 10 years, this metric has ranged from a low of 2.66 to a high of 2.76. The Biotechnology industry median Altman Z-Score is 2.61. Atrium Therapeutics' value of 2.66 is 1.9% above this industry median. Based on the distribution chart, Atrium Therapeutics ranks #463 out of 935 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' Altman Z-Score compare to RNAC and KROS?
According to the Biotechnology industry distribution chart, Atrium Therapeutics ranks #463 out of 935 companies for Altman Z-Score. This puts Atrium Therapeutics in the upper half of its industry. The industry median Altman Z-Score is 2.61. Atrium Therapeutics' value of 2.66 is 1.9% above this benchmark. Historically, Atrium Therapeutics' own Altman Z-Score has ranged from 2.66 to 2.76 over the past decade. While the company's 10-year median is 2.76 vs. the industry median of 2.61, Atrium Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.61, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Atrium Therapeutics's current Altman Z-Score of 2.66 is 1.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Atrium Therapeutics and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atrium Therapeutics's current Altman Z-Score is 2.66, which is near median its own 10-year median of 2.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current Altman Z-Score of 2.66. The current Altman Z-Score is 2.66, which is near median its 10-year median of 2.76 and 1.9% above the Biotechnology industry median of 2.61. Atrium Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current Altman Z-Score is 2.66 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score
Get the complete analysis for RNA
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RNA has been successfully added to your 